Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Meijer, Inc. et al v. Ferring B.V. et al
Case Number:
7:05-cv-02237
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Berger Montague
- Cohen Milstein
- Criden & Love
- Grant & Eisenhofer
- Jones Day
- Kaplan Fox
- Lowey Dannenberg
- Milberg Coleman
- Robins Kaplan
- Spector Roseman
- Zwerling Schachter
Companies
- Aetna Inc.
- Blue Cross Blue Shield Association
- BlueCross BlueShield of Massachusetts
- BlueCross BlueShield of Tennessee Inc.
- EmblemHealth Inc.
- Florida Blue
- Government Employees Health Association Inc.
- Harvard Pilgrim Health Care Inc.
- Hawaii Medical Service Association
- Humana Inc.
- Rochester Drug Cooperative Inc.
Sectors & Industries:
-
March 27, 2013
Insurers Object To $4.8M Ferring, Aventis Antitrust Deal
Aetna Inc. and other insurers on Monday told a New York federal judge they oppose the $4.75 million settlement of a proposed class action accusing Ferring BV and Aventis Pharmaceuticals Inc. of thwarting generic competition for an antidiuretic drug by fraudulently obtaining a patent for it.
-
March 06, 2013
Ferring, Aventis To Pay $4.8M To End Drug Antitrust Suit
Ferring BV and Aventis Pharmaceuticals Inc. have settled for $4.75 million a proposed class' allegations that the companies thwarted generic competition for anti-diuretic drug DDAVP by fraudulently obtaining a patent on it, according to a Tuesday filing in New York federal court.
-
October 18, 2012
Ferring, Aventis Trim Claims In DDAVP Antitrust Class Action
A New York federal judge on Wednesday narrowed claims brought by a proposed class of indirect purchasers of the anti-diuretic drug DDAVP who allege Ferring BV and a Sanofi SA unit suppressed generic competition by fraudulently acquiring a patent on the medication.
-
August 04, 2011
Ferring, Aventis Reach $20M Deal In DDAVP Antitrust Suit
Ferring BV and Aventis Pharmaceuticals Inc. on Wednesday agreed to pay $20.25 million to settle with a proposed class of direct purchasers of DDAVP who claimed in a New York suit that the companies suppressed generic competition by fraudulently acquiring a patent for the diabetes drug.